neuroimmunology-2017-scientifictracks-abstracts

Page 33

Notes:

ISSN:2171-6625

September 18-19, 2017 | Dallas, USA

International Conference on

NEUROLOGY AND NEUROIMMUNOLOGY

rug development in Alzheimer’s disease has moved to

development of disease-modifying therapies in early

stage and pre-clinical disease. With the growing body of

literature in the association of several mid-life risk factors that

have been identified, several large scale, preventive studies

are underway for the prevention of thememory and cognitive

impairments due to Alzheimer’s disease neuropathology and

neurodegeneration. In this presentation, several current and

ongoing Phase 1,2 and 3 studies will be discussed, including

safety and tolerability data of anti-amyloid and anti-tau

monoclonal antibody therapies. There will also be a review

of the current risk factors for development of AD and current

state of understanding of the potential prevention of AD and

related dementias.

Speaker Biography

Diana R Kerwin completed internal medicine residency and geriatric medicine

fellowship training at Northwestern University Feinberg School of Medicine in

Chicago, Ill, and specializes in cognitive disorders. Dr. Kerwin is the Director of the

Texas Alzheimer’s and Memory Disorders program at Texas Health Presbyterian

Hospital-Dallas and Assistant professor in the Department of Neurology and Neuro-

therapeutics at University of Texas Southwestern Medical Center in Dallas. Prior to

founding the program in July 2013, she was Assistant Professor of Medicine-Geriatrics

at Northwestern and faculty in the Northwestern University Cognitive Neurology and

Alzheimer’s Disease Center (CNADC). Dr. Kerwin is the principal investigator on several

Phase 1, 2 and 3 clinical trials for the development of therapeutics in Alzheimer’s and

other dementias such as Progressive Supranuclear Palsy. She is the PI for several NIA

funded studies on the prevention of Alzheimer’s disease, and collaborative studies for

patients with frontotemporal lobe dementia syndromes. Dr. Kerwin’s areas of research

and clinical interests include the prevention of cognitive decline and dementia.

Updateonalzheimer’s diseaseand related-dementias: Amyloidand tau immunotherapydevelopments

and alzheimer’s prevention trials

Diana R Kerwin

University of Texas Southwestern Medical Center, USA

Diana R. Kerwin, J Neurol Neurosci, 8:5

DOI: 10.21767/2171-6625-C1-002